Results 91 to 100 of about 146,499 (323)

Antimicrobial Susceptibility Breakpoints and First-Step parC Mutations in Streptococcus pneumoniae: Redefining Fluoroquinolone Resistance

open access: yesEmerging Infectious Diseases, 2003
Clinical antimicrobial susceptibility breakpoints are used to predict the clinical outcome of antimicrobial treatment. In contrast, microbiologic breakpoints are used to identify isolates that may be categorized as susceptible when applying clinical ...
Sue Lim   +4 more
doaj   +1 more source

Docking and QSAR Studies of Camptothecin Derivatives as Inhibitor of DNA Topoisomerase-I [PDF]

open access: yes, 2011
Camptothecin (CPT) is a cytotoxic quinoline alkaloid which inhibits the DNA enzyme Topoisomerase-I (Topo-I) and has shown remarkable anticancer activity in preliminary clinical trials. The major limitation is its low solubility and high adverse reaction.
Dharmendra K. Yadav   +2 more
core   +2 more sources

Long‐Term Outcomes of Reduced‐Intensity Conditioning Hematopoietic Stem Cell Transplantation for Patients With Systemic Sclerosis With Impaired Cardiac Function

open access: yesArthritis &Rheumatology, EarlyView.
Objective High‐intensity conditioning autologous hematopoietic stem cell transplantation (AHSCT) is standard of care for patients with advanced systemic sclerosis (SSc). The role of reduced‐intensity conditioning (RIC) before AHSCT in this population remains unclear.
Yonatan Lean   +4 more
wiley   +1 more source

Role of Topoisomerase IIβ in DNA Damage Response following IR and Etoposide

open access: yesJournal of Nucleic Acids, 2010
The role of topoisomerase IIβ was investigated in cell lines exposed to two DNA damaging agents, ionising radiation (IR) or etoposide, a drug which acts on topoisomerase II. The appearance and resolution of γH2AX foci in murine embryonic fibroblast cell
Nicola J. Sunter   +4 more
doaj   +1 more source

Effect of developmental changes on pharmacokinetics of drugs used in the treatment of infant acute lymphoblastic leukaemia—A comprehensive review

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis   +5 more
wiley   +1 more source

In systemic sclerosis skin perfusion of hands is reduced and may predict the occurrence of new digital ulcers [PDF]

open access: yes, 2017
Systemic sclerosis (SSc) patients are at high risk for the development of ischemic digital ulcers (DUs). The aim of this study was to assess in SSc patients a correlation between skin perfusion evaluated by LDPI and DUs and to evaluate the prognostic ...
Barbano, Biagio   +6 more
core   +1 more source

Model‐informed precision dosing of carboplatin in cancer patients by leveraging myelosuppression data from electronic health records

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aims This study aimed to develop and validate a population pharmacokinetic‐pharmacodynamic (pop‐PK‐PD) model to describe carboplatin‐induced myelosuppression in cancer patients and support dose individualization. Methods Data from 580 cancer patients treated with carboplatin at Amsterdam UMC between 2019 and 2022 were used for model ...
Alessandro De Carlo   +10 more
wiley   +1 more source

RNase H enables efficient repair of R-loop induced DNA damage. [PDF]

open access: yes, 2016
R-loops, three-stranded structures that form when transcripts hybridize to chromosomal DNA, are potent agents of genome instability. This instability has been explained by the ability of R-loops to induce DNA damage. Here, we show that persistent R-loops
Amon, Jeremy D, Koshland, Douglas
core   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy